文献
J-GLOBAL ID:201802239664863270
整理番号:18A0817583
中間または不良リスクの転移性腎細胞癌に対する初期治療としてのカボザチニブ対スニチニブ 非依存的レビューおよび全生存更新による無増悪生存率【JST・京大機械翻訳】
Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update
著者 (16件):
Choueiri Toni K.
(Dana-Farber/Partners CancerCare, Boston, MA, USA)
,
Hessel Colin
(Exelixis Inc., South San Francisco, CA, USA)
,
Halabi Susan
(Department of Biostatistics and Bioinformatics, Duke University, Durham, NC, USA)
,
Sanford Ben
(Alliance Statistics and Data Center, Duke University, Durham, NC, USA)
,
Michaelson M. Dror
(Massachusetts General Hospital Cancer Center, Boston, MA, USA)
,
Hahn Olwen
(Alliance Protocol Operations Office, Chicago, IL, USA)
,
Walsh Meghara
(Dana-Farber/Partners CancerCare, Boston, MA, USA)
,
Olencki Thomas
(The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA)
,
Picus Joel
(Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO, USA)
,
Small Eric J.
(UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA)
,
Dakhil Shaker
(University of Kansas - Wichita, Wichita, KS, USA)
,
Feldman Darren R.
(Memorial Sloan Kettering Cancer Center, New York, NY, USA)
,
Mangeshkar Milan
(Exelixis Inc., South San Francisco, CA, USA)
,
Scheffold Christian
(Exelixis Inc., South San Francisco, CA, USA)
,
George Daniel
(Duke Cancer Institute, Duke University Medical Center, Durham, NC, USA)
,
Morris Michael J.
(Memorial Sloan Kettering Cancer Center, New York, NY, USA)
資料名:
European Journal of Cancer
(European Journal of Cancer)
巻:
94
ページ:
115-125
発行年:
2018年
JST資料番号:
A0802C
ISSN:
0959-8049
資料種別:
逐次刊行物 (A)
記事区分:
原著論文
発行国:
オランダ (NLD)
言語:
英語 (EN)